RE: Accustem expected valuation4 Nov 2020 12:40
Ok Schomo, I’ll do it, if nobody else wants to lol.
The £4.03m you refer to was for tax purposes and was a nominal amount put forward to HMRC by the company as a rough figure for R & D of StemPrinter, it has nothing to do with it’s actual value. It has not been officially valued but it is 40% more accurate than Oncotype DX, the market leader, which was sold for $2.8b last year.
A leading analyst has put a ballpark figure of $280m on StemPrinter, but that is based on nothing more than 10% of Oncotype DX.
What is more telling, is that there is currently a disconnect between the Nasdaq SP and Aim of about 30% or £70m, so it looks like, in order to manipulate the share price the MM are making up their own rules again and trying to make out that because Nasdaq hasn’t yet passed the ex entitlement date, they are entitled to keep this disparity until Friday. This of course as absolute B00lox because both U.K. and US sell shares from the same pot and sells and buys should affect both sides of the pond in equal measure.
What I’m saying is the MM’s are playing both sides against the middle (as usual) and thus far are valuing AccuStem at £70m (they may decide to change this valuation at any time they wish by raising then Nasdaq price or dropping AIM if they feel like it) when, like the rest of us, they have absolutely no idea what the value is. They are using the uncertainty to rid PI’s of their shares, as usual. Imo